Philippe Drechsle

Direct headcount: 34

In addition to previous role, responsible for EU Pipeline (product selection, collaboration with R&D to define development strategy, evaluation of 3rd parties ad-hoc opportunities)

Since March 2022: Member of the Medicines for Europe Executive Board

Achievements

• Review of pipeline strategy, resulting in 80 MEUR savings
• Successful launch execution (budgetary achievement or over-achievement) during period, adding 200-300 MEUR annual net sales
• Successful shaping of major EU legislative updates (Pharma Legislation, Critical Medical Alliance) and reopening of the UWWTD.

Direct headcount: 29

Managing new product launches for Europe, from development to post-launch phase (1 year after launch), including defining litigation strategies for launches at risk

Responsible for Teva’s relationship with the Monitoring Trustee /EU Case Team and the business partners for the 2017 divested business (anti-trust related EU divestment following the Actavis acquisition)

Achievements

• Successful launch execution during period, adding between 140-270 MEUR annual net sales
• Successful and smooth transition of divested business

Direct headcount: 6

Identification of portfolio needs with commercial units, cost optimization of the existing portfolio by identifying in-house product source harmonization/saving potential and 3rd party product saving potential, tail-cut management of small volume/low profit products

Coordination of all functional leads involved in the execution of Falsified Medicine Directive/Serialization. Member of the Medicines for Europe FMD steering committee

Achievements

• Generated annual savings of over 30 MEUR
• Successful implementation of FMD

Responsible for the maximization of early product launches

Preparation of the benefit/risk profile by project involving Patent/Legal attorneys and Country Managers and participation in the decision-making process

Achievements

• Implementation of new launch at risk process and evaluation tool
• Evaluation of over 250 projects, total sales potential of 55 MEUR
• Additional sales in 2013 of 33 MEUR

Direct headcount: 2 experienced Associate Directors

Responsible for licensing-in project prioritization, project allocation and timely and cost-effective sourcing of defined product portfolio

Direct headcount: 5, Indirect headcount: 120

Responsible for Portugal, Central America/Ecuador and Asia (total sales of 55 MCHF, 120 heads), full P&L responsibility over the region

Definition of long-term strategy (resource allocation, product portfolio, regulatory affairs, sales & marketing, warehousing and partnership with local distributors) and yearly budget together with local management

Direct headcount: 10

In addition to Management Services assignment, responsible for Sales Operations.

Supervision of the administrative part of the international sales (150-180 MCHF)

Responsible for the adequate and efficient implementation of sales administrative processes (organization, expenses, accounts receivable, reporting)

Direct headcount: 5

Responsible for the sales forecasting process and the development of proper interface with operations

Responsible for the product launch/change management process

Implementation of controlling, administrative and budgeting processes

Active participation in commercial restructuring (acquisition of Mepha Baltic, distributor change in Ecuador, restructuring in Kuwait, closing of unprofitable markets, divestiture in Egypt)

Engaged from Junior Auditor to Audit Manager for significant, international companies in retail, trade and pharmaceuticals (e.g. H&M, Bata, Roche financial companies, Knoll)
“EY Global Biotechnology Report” team member